In the A-Day presentation, they mention dac and ovarian cancer. The response rates are excellent. In 70% of pts they saw response rates. This is why they went after Ovarian cancer with sgi-110. Med PFS with dac was 309 Days.
AT13387 hits multiple targets that Abiraterone misses. This combination could reverse resistance. The other key both these drugs can be given for years and even during progression.
At ACCR they will present 11 abstracts
5 with sgi-110
1 LEE011 by novartis
1 IAP Preclinical
Certainly positive news. Unfortunately, we don't have enough "believers" buying the stock. Hopefully, this will change. With the cash position of the company, and the potenial in the pipeline, this company is way too cheap in my opinion.
Yawn, wake me up when they have something ready to sell. I am tired of hearing about the comics. Endless papers of what if and “just around the corner”. The point is they have NEVER EVER produce a SINGE drug ready for sale.
Hey, maybe next quarter!
Now you know how we feel when you post THINK. That's actually the one thing you don't do is think. You thought selling at 2.31 was smart. If they had one single drug ready for sale, the share price would be $10. Only a duffice would post such gargle.
I understand the benefits of s110 but remember 5+ years of management hype to get it into the clinics. Another 5 years and the 130 mil is gone, the 75 mil yearly Dacogen revenues will be gone but management bonuses and stock options continue.